Literature DB >> 3455634

Bone histomorphometry of renal osteodystrophy in diabetic patients.

D L Andress1, G Hercz, J B Kopp, D B Endres, K C Norris, J W Coburn, D J Sherrard.   

Abstract

Bone biopsies and plasma parathyroid hormone (PTH) from 27 diabetic dialysis patients were compared to biopsies and PTH levels from matched patients without diabetes to determine if PTH has a role in preserving bone mass in diabetic renal osteodystrophy. Significantly lower values were present in the diabetic group for mineralized bone area (p less than 0.003), osteoblastic osteoid (p less than 0.01), resorptive surface (p less than 0.001), fibrosis (p less than 0.005), bone apposition rate (p less than 0.01), bone formation rate (BMU level) (p less than 0.04), and plasma PTH (p less than 0.05). Bone-surface aluminum was higher in the diabetic group (44 +/- 5% vs. 20 +/- 5%, p less than 0.005). Linear regression analysis revealed significant positive correlations of mineralized bone area with time on dialysis, bone formation rate, bone resorption, and PTH only in the group without diabetes. While both groups had significant positive correlations of PTH with osteoblastic osteoid and bone resorption, only in the nondiabetic group was there a positive correlation of PTH with bone apposition and bone formation rate (BMU level), observations suggesting that the lower bone formation in the diabetic patients may have arisen in part from a failure of PTH to promote bone mineralization. We conclude that relatively low PTH levels and high bone aluminum in diabetic patients with chronic renal failure may be responsible in part for low bone mass when compared to uremic patients without diabetes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3455634     DOI: 10.1002/jbmr.5650020609

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  9 in total

1.  Diabetic bone disease.

Authors:  R Bouillon
Journal:  Calcif Tissue Int       Date:  1991-09       Impact factor: 4.333

2.  Long-term fracture risk following renal transplantation: a population-based study.

Authors:  Line M Vautour; L Joseph Melton; Bart L Clarke; Sara J Achenbach; Ann L Oberg; James T McCarthy
Journal:  Osteoporos Int       Date:  2003-12-09       Impact factor: 4.507

Review 3.  Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders.

Authors:  Hajime Sasaki; Kimito Hirai; Christine M Martins; Hisako Furusho; Ricardo Battaglino; Koshi Hashimoto
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

4.  Diabetes, biochemical markers of bone turnover, diabetes control, and bone.

Authors:  Jakob Starup-Linde
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-08       Impact factor: 5.555

5.  Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease.

Authors:  Patricia Wahl; Huiliang Xie; Julia Scialla; Cheryl A M Anderson; Keith Bellovich; Carolyn Brecklin; Jing Chen; Harold Feldman; Orlando M Gutierrez; Jim Lash; Mary B Leonard; Lavinia Negrea; Sylvia E Rosas; Amanda Hyre Anderson; Raymond R Townsend; Myles Wolf; Tamara Isakova
Journal:  Diabetes Care       Date:  2012-03-23       Impact factor: 19.112

6.  Adynamic bone disease-bone and beyond.

Authors:  Vincent M Brandenburg; Jürgen Floege
Journal:  NDT Plus       Date:  2008-06

7.  The Importance of Biologically Active Vitamin D for Mineralization by Osteocytes After Parathyroidectomy for Renal Hyperparathyroidism.

Authors:  Aiji Yajima; Ken Tsuchiya; David B Burr; Joseph M Wallace; John D Damrath; Masaaki Inaba; Yoshihiro Tominaga; Shigeru Satoh; Takashi Nakayama; Tatsuhiko Tanizawa; Hajime Ogawa; Akemi Ito; Kosaku Nitta
Journal:  JBMR Plus       Date:  2019-10-23

Review 8.  Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.

Authors:  Jianzhen Ye; Guangrui Deng; Feng Gao
Journal:  Drug Des Devel Ther       Date:  2018-04-19       Impact factor: 4.162

Review 9.  Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony.

Authors:  Stanley M H Yeung; Stephan J L Bakker; Gozewijn D Laverman; Martin H De Borst
Journal:  Curr Diab Rep       Date:  2020-08-28       Impact factor: 4.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.